Found: 8
Select item for more details and to access through your institution.
Mechanism of cisplatin resistance in gastric cancer and associated microRNAs.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2023, v. 92, n. 5, p. 329, doi. 10.1007/s00280-023-04572-1
- By:
- Publication type:
- Article
Quantitative proteomics profiling reveals the inhibition of trastuzumab antitumor efficacy by phosphorylated RPS6 in gastric carcinoma.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2023, v. 92, n. 5, p. 341, doi. 10.1007/s00280-023-04571-2
- By:
- Publication type:
- Article
Chemotherapy periodization to maximize resistance training adaptations in oncology.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2023, v. 92, n. 5, p. 357, doi. 10.1007/s00280-023-04576-x
- By:
- Publication type:
- Article
A clinical trial of zosuquidar plus gemtuzumab ozogamicin (GO) in relapsed or refractory acute myeloid leukemia (RR AML): evidence of efficacy based on leukemic blast P-glycoprotein functional phenotype.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2023, v. 92, n. 5, p. 369, doi. 10.1007/s00280-023-04578-9
- By:
- Publication type:
- Article
Clinical significance of KL-6 in immune-checkpoint inhibitor treatment for non-small cell lung cancer.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2023, v. 92, n. 5, p. 381, doi. 10.1007/s00280-023-04573-0
- By:
- Publication type:
- Article
Influence of CYP3A5 and ABCB1 polymorphisms on the pharmacokinetics of vincristine in adult patients receiving CHOP therapy.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2023, v. 92, n. 5, p. 391, doi. 10.1007/s00280-023-04580-1
- By:
- Publication type:
- Article
Population pharmacokinetics and pharmacogenetics analyses of imatinib in Chinese patients with chronic myeloid leukemia in a real-world situation.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2023, v. 92, n. 5, p. 399, doi. 10.1007/s00280-023-04581-0
- By:
- Publication type:
- Article
Pharmacokinetics, safety, tolerability, and feasibility of apatinib in combination with gefitinib in stage IIIB-IV EGFR-mutated non-squamous NSCLC: a drug-drug interaction study.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2023, v. 92, n. 5, p. 411, doi. 10.1007/s00280-023-04563-2
- By:
- Publication type:
- Article